Thursday, May 8, 2014
BioLineRx Ltd.'s deal with the University of Colorado could give the
biotech a disease-modifying therapy for cutaneous fibrosis in patients with
diffuse systemic scleroderma.1 It is still unclear whether the
university's toll-like receptor 4 inhibitors will work
in other tissues affected by the disease.
told SciBX that one of his next steps is developing TLR4 inhibitors.
unanswered question is whether TLR4 also underlies fibrosis in other organs.
Martz, L. SciBX 7(18);
Published online May 8, 2014
1. Bhattacharyya, S. et al. Sci. Transl. Med.; published
online April 16, 2014; doi:10.1126/scitranslmed.3008264
Swati Bhattacharyya, Northwestern
University Feinberg School of Medicine, Chicago, Ill.
Varga, same affiliation as above
2. Varga, J. et al. Biochem. J. 247,
3. Rajkumar, V.S. et al. Arthritis Res. Ther. 7, R1113-R1123 (2005)
4. Bhattacharyya, S. et al. Am. J. Pathol. 182,
5. Ciechomska, M. et al. Expert Rev. Mol. Med. 15, e9; published online Aug. 28, 2013;
AND INSTITUTIONS MENTIONED
(Tel Aviv:BLRX; NASDAQ:BLRX), Jerusalem, Israel
South San Francisco, Calif.
Northwestern University, Chicago, Ill.
Northwestern University Feinberg School of Medicine, Chicago, Ill.
Scleroderma Research Foundation, San Francisco, Calif.
University of Colorado, Denver, Colo.
University of Colorado at Boulder, Boulder, Colo.
University of Michigan, Ann Arbor, Mich.